Aelis Farma Reports 2025 Half-Year Financial Results and Presents Progress and Development Outlook [Yahoo! Finance]
Indivior PLC - Ordinary Shares (INDV)
Company Research
Source: Yahoo! Finance
cannabis use disorders (CUD) with the CB -SSi AEF0117, which further validated the new pharmacological class of CB -SSi by confirming the compound's safety and its ability to reduce cannabis consumption, although the primary endpoint was not reached. Significant progress in preparing the multicentre Phase 2b study with AEF0217 for the treatment of behavioural deficits associated with Down syndrome, which is scheduled to start in the second half of 2025, in line with the announced plan. Rigorous cost management, resulting in a solid cash position of €10.8 million as of 30 June 2025, providing financial visibility beyond 2026, which could be further extended through additional non-dilutive funding. BORDEAUX, France, September 22, 2025 BUSINESS WIRE )--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving the CB receptor, today announce
Show less
Read more
Impact Snapshot
Event Time:
INDV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INDV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INDV alerts
High impacting Indivior PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
INDV
News
- Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Indivior (NASDAQ:INDV) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- A Fresh Look at Indivior (INDV) Valuation Following Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Indivior Concludes Legacy U.S. Department of Justice Matter [Yahoo! Finance]Yahoo! Finance
- Indivior Concludes Legacy U.S. Department of Justice MatterPR Newswire
INDV
Earnings
- 10/30/25 - Beat
INDV
Sec Filings
- 11/20/25 - Form 8-K
- 11/14/25 - Form 8-K
- 11/13/25 - Form SCHEDULE
- INDV's page on the SEC website